Lixisenatide: First Global Approval

@article{Elkinson2013LixisenatideFG,
  title={Lixisenatide: First Global Approval},
  author={Shelley Elkinson and Gillian M. Keating},
  journal={Drugs},
  year={2013},
  volume={73},
  pages={383-391}
}
The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia®) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin secretion in a glucose-dependent manner, as well as suppressing glucagon production and slowing gastric emptying. A once-daily subcutaneous formulation of lixisenatide has been… 
View on Springer
ncbi.nlm.nih.gov
27 Citations
Background Citations
8

27 Citations

Citation Type

Citation Type

Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies
TLDR
This article provides a review of lixisenatide, a once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes.
Lixisenatide: a guide to its use as add-on therapy in type 2 diabetes mellitus
TLDR
In clinical trials in this patient population, add-on therapy with once-daily subcutaneous lixisenatide improved glycaemic control, had beneficial effects on bodyweight and was generally well tolerated.
Lixisenatide as add-on therapy to basal insulin
TLDR
Lixisenatide exerts profound effects on postprandial glucose through established mechanisms of glucose-dependent insulin secretion and glucagon suppression in combination with delayed gastric emptying, making it a novel incretin agent for use in combinationWith optimally titrated basal insulin.
Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson's disease.
TLDR
Both liraglutide and lixisenatide are superior to exendin-4, and both drugs show promise as a novel treatment of PD.
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
TLDR
GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions because of the substantial body of evidence that these mimetics have neuroprotective and anti-inflammatory effects.
AUTHOR COPY ONLY Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
TLDR
GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions because of the substantial body of evidence that these mimetics have neuroprotective and anti-inflammatory effects.
Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease
Pharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon.
The effect of liraglutide on endothelial function in patients with type 2 diabetes
TLDR
Liraglutide did not significantly impact endothelium-dependent vasodilation after 12 weeks; however, additional investigations looking at the effect of liragLutide on endothelial function in alternative vasculature and during the postprandial period are warranted.
...
1
2
3
...

References

SHOWING 1-10 OF 36 REFERENCES
The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
TLDR
Clinical trials involving patients with T2DM have provided evidence for improved glucose tolerance, weight loss and lowered hemoglobin A1c (HbA1c) causing a significantly higher percentage of patients to achieve target HbA 1c compared with placebo.
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
TLDR
The results of phase III trials are awaited for confirmation of the anticipated effects of lix Eisenatide on glycemic measures and weight; favorable results would place lixisenatide for consideration among other GLP-1R agonists in the treatment armamentarium for T2DM.
Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes
TLDR
Lixisenatide improves glycemic control, by primarily affecting PPG, while preventing weight gain or reducing body weight with a low risk of hypoglycemia in T2DM.
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus
TLDR
A brief overview of the mechanism of action is given, the clinical data available on exenatide and liraglutide as established substances are summarized and the placement of GLP-1 receptor agonists in the treatment algorithm of type 2 diabetes is discussed.
Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
TLDR
Once-daily lixisenatide monotherapy significantly improved glycemic control with a pronounced postprandial effect (75% reduction in glucose excursion) and was safe and well tolerated in type 2 diabetes.
Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice
TLDR
Long-term treatment of diabetic db/db mice with ZP10A resulted in a dose-dependent improvement of FBG, glucose tolerance, and blood glucose control, and the data suggest that ZP 10A preserves β-cell function.
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
Diabet. Med. 27, 1024–1032 (2010)
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*
TLDR
To assess the efficacy and safety of once‐daily lixisenatide versus placebo in Asian patients with type 2 diabetes insufficiently controlled on basal insulin ± sulfonylurea, a large number of patients will need to be referred to Europe for further studies.
...
1
2
3
4
...